NASDAQ •
Healthcare •
Biotechnology •
Quote as of 09/17/2026 16:00
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization3,690.9 mln
Float254 mln
Earnings Date11/10/2026
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.26
Borderline
1-Year Forecast
17.12
Strong upside
Relative Strength
95
/ 100
Top performer
Debt / Equity
0.15
Very low leverage
Pre-Tax Margin
-297%
Severely loss-making
Business Description
Founded in 2012 and based in Vancouver, Canada, AbCellera Biologics works to find and build new antibody treatments for patients who currently have few good options. The company has two drugs moving through clinical trials: one non-hormonal treatment for hot flashes and night sweats, and another targeting certain immune system disorders like atopic dermatitis. AbCellera works alongside major partners including Eli Lilly, AbbVie, and Biogen to advance its research and bring new medicines to market.
